{"id":"investigational-live-attenuated-mumps-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Parotitis"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains a live but weakened (attenuated) mumps virus strain that replicates in the body without causing disease. This triggers both cellular and humoral immune responses, generating antibodies and T-cell memory against mumps virus antigens. Upon exposure to wild-type mumps virus, the primed immune system can rapidly neutralize the pathogen and prevent infection or severe disease.","oneSentence":"A live attenuated mumps vaccine stimulates the immune system to recognize and protect against mumps virus infection by using a weakened form of the virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:57.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mumps prevention"}]},"trialDetails":[{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05065177","phase":"PHASE3","title":"Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2016-01","conditions":"Mumps","enrollment":1140},{"nctId":"NCT01702428","phase":"PHASE3","title":"Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-09","conditions":"Rubella, Measles, Mumps","enrollment":5016},{"nctId":"NCT02692599","phase":"PHASE3","title":"Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2016-01","conditions":"Mumps","enrollment":1150},{"nctId":"NCT00560755","phase":"PHASE3","title":"Safety Study of ProQuad® rHA in Infants (V221-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-24","conditions":"Measles, Mumps, Rubella","enrollment":3388}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Investigational live attenuated mumps vaccine","genericName":"Investigational live attenuated mumps vaccine","companyName":"Sinovac Research and Development Co., Ltd.","companyId":"sinovac-research-and-development-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"A live attenuated mumps vaccine stimulates the immune system to recognize and protect against mumps virus infection by using a weakened form of the virus. Used for Mumps prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}